TherapeuticsMD, Inc.
PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE
Last updated:
Abstract:
This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
Status:
Application
Type:
Utility
Filling date:
15 Jun 2021
Issue date:
10 Feb 2022